New drug duo aims to tackle tough lymphoma in immunocompromised patients
NCT ID NCT06723457
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining epcoritamab (an immunotherapy that directs immune cells to kill lymphoma) with lenalidomide (which boosts the immune system) can shrink tumors in 34 patients whose immunodeficiency-related large B-cell lymphoma has not responded to treatment or has returned. The main goal is to see how many patients achieve a complete response within six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epcoritamab and lenalidomide
What this could lead to
If successful, this combination could offer a new treatment option for patients with hard-to-treat immunodeficiency-related lymphoma who cannot tolerate chemotherapy.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply broadly. The combination may cause side effects or fail to improve response rates over existing therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States